PARIS & BOSTON--(BUSINESS WIRE)--Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced a business update.

As a result of the disruption from the global crisis caused by the coronavirus, or COVID-19, the company is changing its date for publication of full year 2019 financial results to Tuesday, April 28, 2020 after markets close at 5:45 PM CET (Paris time). The company intends to provide an update on sales results for the first quarter of 2020 as part of this publication as well. The Mauna Kea Technologies management team will hold an English-language conference call at 6:00 PM CET, Paris time (1:00 PM EDT, New York time), to discuss full year 2019 financial results, first quarter of 2020 sales results and will address investor and analyst questions.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com